Catalyst Biosciences Inc (CBIO) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Catalyst Biosciences Inc (CBIO:NASDAQ), powered by AI.
- Current Price
- $17.92
- P/E Ratio
- -1.2
- Market Cap
- 187M
- Sector
- Healthcare
What is the Catalyst Biosciences Inc stock price forecast?
Catalyst Biosciences Inc is currently trading at $17.92. View real-time AI analysis on Alpha Lenz.
What is Catalyst Biosciences Inc insider trading activity?
View the latest insider trading data for Catalyst Biosciences Inc on Alpha Lenz.
What is Catalyst Biosciences Inc's P/E ratio?
Catalyst Biosciences Inc's P/E ratio is -1.2.
Catalyst Biosciences Inc
NASDAQ · CBIO“Catalyst Biosciences Inc trades at a P/E of -1.2 (undervalued) with modest ROE of -164.2%. 3Y revenue CAGR of 139.0% highlights clear growth momentum.”
Ask for details →Company Overview
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company is headquartered in Waltham, Massachusetts.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Catalyst Biosciences Inc trades at a P/E of -1.2 (undervalued) with modest ROE of -164.2%. 3Y revenue CAGR of 139.0% highlights clear growth momentum.”
Ask for details →Frequently Asked Questions
Catalyst Biosciences Inc (ticker: CBIO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 33 employees. Market cap is $187M.
The current price is $17.92 with a P/E ratio of -1.21x and P/B of 0.92x.
ROE is -164.18% and operating margin is -1407.52%. Annual revenue is $11M.